Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen

Borderline resectable pancreatic cancer (BRPC) is a potentially resectable disease but is associated with poorer survival compared to primary resectable disease. There has been no prospective trial that compare the efficacy of FOLFIRNOX and gemcitabine-based regimen for BRPC. Between February 2013 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Kang, Jihoon, Kim, Kyu-Pyo, Lee, Jae-Lyun, Ryoo, Baek-Yeol, Chang, Heung-Moon, Lee, Sang Soo, Park, Do Hyun, Song, Tae Jun, Seo, Dong Wan, Lee, Sung Koo, Kim, Myung-Hwan, Park, Jin-Hong, Hwang, Dae Wook, Song, Ki Byung, Lee, Jae Hoon, Kim, Song Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542271/
https://www.ncbi.nlm.nih.gov/pubmed/28564637
http://dx.doi.org/10.18632/oncotarget.17940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542271/
https://www.ncbi.nlm.nih.gov/pubmed/28564637
http://dx.doi.org/10.18632/oncotarget.17940

Ejemplares similares